News and Updates

Breakthrough T1D is excited to announce that the T1D Fund portfolio company Protomer Technologies, who is developing "smart" insulin, has been acquired by Eli Lilly.

The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.

There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of the key takeaways from the conference.

Here is Dr. Camillo Ricordi to share his key takeaways from day 4 from the American Diabetes Association's Scientific Sessions.

Here are Drs. Jennifer Sun, Dana Lewis, and Christine Wang to share their key takeaways from day 3, with their commentary in the video and below.

Drs. Danny Chou, Peter Arvan, Jeffrey Millman, and Efsun Arda will share their key takeaways from day 2, with their commentary in the video and below.

Here are Drs. Candace Reno and Luiza Caramori share their key takeaways from day 1, with their commentary in the video and below.

Breakthrough T1D and IBM Research have published their first paper, applying world-class computing power to identify factors leading to the onset of T1D in children.

At the ADA's 81st Scientific Sessions, healthcare professionals will gather at one of the largest conferences of diabetes researchers in the world.

How Breakthrough T1D’s screening education and awareness program can help address health disparities experienced by underserved members of the T1D community.